Estrella Immunopharma to Participate in the D. Boral Capital Global Conference
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, today announced that its CEO and CFO will participate in one-on-one investor meetings at the D. Boral Capital 2026 Global Conference. Hosted by D. Boral Capital, this curated forum at The Plaza Hotel brings together executives from emerg.
Business Wire5/5/2026Neutral